Noninvasive Monitoring of Glioma Growth in the Mouse

Alessandrini, Francesco; Ceresa, Davide; Appolloni, Irene; Marubbi, Daniela; Malatesta, Paolo

doi:10.7150/jca.15564

Cited by 14 publications

(21 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As is known, malignant tumour progression is a dynamic process which is accompanied by an altered molecular phenotype 3 including emergence of novel molecular alterations or the loss of previously alterations, such as gene mutation, DNA promoter methylation and chromosome codeletion. Whether there was new occurrence of IDH1 R132H mutation in astrocytoma recurrence?…”

Section: Introductionmentioning

confidence: 99%

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours

et al. 2017

J. Cancer

View full text Add to dashboard Cite

IDH1 R132H mutation is an important marker of survival in patients with gliomas. Although there are many changes of genes in tumour malignant progression, IDH1 R132H mutation status in glioma progression remained unclear. Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV). Meanwhile, the DNA was isolated from paired samples, and PCR amplification was used for IDH1 exon4 sequencing. Nonparametric test, KM and Cox models were used to examine the statistical difference and survival function. We found that the percent of IDH1 R132H mutation was 68.6% (24/35) in pLGA group, but no IDH1 mutation was found in pPA and pHGA groups. Meanwhile, the results from immunohistochemistry and DNA sequencing showed that, compared with primary astrocytoma, there was no change of IDH1 status in recurrent astrocytoma whatever tumour pathological grade raise or indolent. The pPA group has the longest recurrence-free period (RFP) and overall survival (OS) in three groups (p<0.01), while the pHGA group has the shortest ones (p<0.01). In pLGA group, the IDH1 R132H mutation subgroup has longer RFP than IDH1 wild type subgroup (p<0.01), but the OS has no statistical difference between two subgroups (p>0.6). Additionally, IDH1 R132H mutation independently predicted a long RFP in patients with pLGA (HR 1.073, 95% CI 0.151-0.775, p<0.01).

show abstract

Section: Introductionmentioning

confidence: 99%

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Evaluation of BBB Penetrating Ability of FluoroMags : Glioma animal model was obtained by stereotactical injections of 10 5 human GBM tumor initiating cells engineered with pCAG:Ds‐Red and pCAG:mGFP‐Gluc into the left forebrain (1.5 mm lateral and 1 mm anterior to bregma, at a 2.5 mm depth from the skull surface) of Nod/Scid mice . This way, the tumor size and the intracranial growth of gliomas were easily detectable by fluorescence microscopy as luciferase Ds‐Red positive areas (Figure S5, Supporting Information).…”

Section: Methodsmentioning

confidence: 99%

“…On the other hand, the fluorescent dye gives a feedback on the biological environment dysregulation toward the acidic conditions mapping the disease evolution in sampled tissues with microscopic resolution. In order to highlight their potential for clinical use, we demonstrate that fluoromagnetic nanotubes systemically injected into an experimental model of glioma are indeed able to migrate across the BBB while maintaining their pH‐sensitive fluorescence and magnetic properties . Furthermore, the in vivo massive presence of systemically injected nanoprobes within the tumor suggests an effective tissue penetration, likely mediated by fenestrated tumor vessels .…”

Section: Introductionmentioning

confidence: 95%

“…The main objective of this experiment is to explore the BBB penetration ability of FluoroMags. A group of four Ds‐Red positive glioma animal models were systemically injected with 500 µg of FluoroMags dispersed in phosphate buffer saline (PBS), while a group of five Ds‐Red positive glioma model was treated with pure PBS as control (Figure S7, Supporting Information) . After euthanasia, FluoroMags has been localized within the brain by H&E immunohistochemistry.…”

Section: In Vivo Experimentsmentioning

confidence: 99%

See 1 more Smart Citation

Self‐Assembled pH‐Sensitive Fluoromagnetic Nanotubes as Archetype System for Multimodal Imaging of Brain Cancer

Villa

Campione

González

et al. 2018

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Fluoromagnetic systems are recognized as an emerging class of materials with great potential in the biomedical field. Here, it is shown how to fabricate fluoromagnetic nanotubes that can serve as multimodal probes for the imaging and targeting of brain cancer. An ionic self-assembly strategy is used to functionalize the surface of synthetic chrysotile nanotubes with pH-sensitive fluorescent chromophores and ferromagnetic nanoparticles. The acquired magnetic properties permit their use as contrast agent for magnetic resonance imaging, and enable the tracking of tumor cell migration and infiltration responsible for metastatic growth and disease recurrence. Their organic component, changing its fluorescence attitude as a function of local pH, targets the cancer distinctive acidity, and allows localizing and monitoring the tumor occurrence and progression by mapping the acidic spatial distribution within biopsy tissues. The fluoromagnetic properties of nanotubes are preserved from the in vitro to the in vivo condition and they show the ability to migrate across the blood brain barrier, thus spontaneously reaching the brain tumor after injection. The simplicity of the synthesis route of these geomimetic nanomaterials combined with their demonstrated affinity with the in vivo condition strongly highlights their potential for developing effective functional materials for multimodal theranostics of brain cancer.

show abstract

“…Presently, of all copepod luciferases, mainly the MLuc from M. longa (MLuc164) and, to a greater extent, Gaussia luciferase, are widely used in noninvasive bioimaging in vivo . Examples of applications include monitoring of secreted target proteins fused to GpLuc, in instance, human insulin and secreted intrapulmonary and circulatory proteins in mice for monitoring gene therapy ; the real‐time tracking of tumor cells, in instance, detection of viable circulating prostate cancer cells in blood by prostate tumor‐selective reporter adenovirus labeled with MLuc , GpLuc monitoring models of human mast cell leukemia and malignant glioma in mice for preclinical studies; and others. Since the bioluminescent signal from the live cell expressing secreted luciferase significantly attenuates in vivo due to dilution, this could be overcome by modification of the reporter in membrane‐anchored form.…”

Section: Application Of Copepod Luciferasesmentioning

confidence: 99%

Shining Light on the Secreted Luciferases of Marine Copepods: Current Knowledge and Applications

Markova

Larionova

Vysotski

2019

Photochem & Photobiology

View full text Add to dashboard Cite

Copepod luciferases—a family of small secretory proteins of 18.4–24.3 kDa, including a signal peptide—are responsible for bright secreted bioluminescence of some marine copepods. The copepod luciferases use coelenterazine as a substrate to produce blue light in a simple oxidation reaction without any additional cofactors. They do not share sequence or structural similarity with other identified bioluminescent proteins including coelenterazine‐dependent Renilla and Oplophorus luciferases. The small size, strong luminescence activity and high stability, including thermostability, make secreted copepod luciferases very attractive candidates as reporter proteins which are particularly useful for nondisruptive reporter assays and for high‐throughput format. The most known and extensively investigated representatives of this family are the first cloned GpLuc and MLuc luciferases from copepods Gaussia princeps and Metridia longa, respectively. Immediately after cloning, these homologous luciferases were successfully applied as bioluminescent reporters in vivo and in vitro, and since then, the scope of their applications continues to grow. This review is an attempt to systemize and critically evaluate the data scattered through numerous articles regarding the main structural features of copepod luciferases, their luminescent and physicochemical properties. We also review the main trends of their application as bioluminescent reporters in cell and molecular biology.

show abstract

Noninvasive Monitoring of Glioma Growth in the Mouse

Cited by 14 publications

References 19 publications

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours

Self‐Assembled pH‐Sensitive Fluoromagnetic Nanotubes as Archetype System for Multimodal Imaging of Brain Cancer

Shining Light on the Secreted Luciferases of Marine Copepods: Current Knowledge and Applications

Contact Info

Product

Resources

About